today announced a new pooled analysis of data from eight Olumiant [®] (baricitinib) clinical trials, showing that baricitinib-treated and placebo-treated patients with moderate-to-severe rheumatoid arthritis (RA) had similar rates of serious infection incidents.
Posted: 2017-06-16 14:06:00
